Novel compounds
AssigneeSoren Ebdrup Et Al
InventorsAnders Klarskov Petersen, Soren Ebdrup
Life of this patent
Estimating the term…
Abstract
Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.
Claims17
A compound of the general formula (I):
- wherein R1 is selected from the group consisting of:
- wherein the symbol * denotes the point of attachment,
- R2 is selected from the group consisting of phenyl substituted with one or two independently selected R3 and pyridinyl substituted with one or two independently selected R3;
- R3 is selected from the group consisting of halogen, cyano, —C(═O)OH, —C(═O)R4, —CH(OH)R4, C(═O)—NR6R7, —OR4, —SR4, —S(═O)2R4, —S(═O)2—NR6R7, —C═CR4R5, —C≡C—R4R5, —C3-C10heterocyclyl optionally substituted with halogen or methyl, C3-C10cycloalkyl optionally substituted with halogen, methyl or hydroxy, phenyl optionally substituted with —C(═O)OH, halogen or methyl, C1-C6alkyl optionally substituted with R4 and heteroaryl optionally substituted with —C(═O)OH, halogen or methyl;
- R4 is selected from the group consisting of hydrogen, C1-C6alkyl, phenyl, heteroaryl and C3-C10cycloalkyl, wherein said C1-C6alkyl, phenyl, heteroaryl and C3-C10cycloalkyl are optionally substituted with —C(═O)OH, —CH2OH, halogen, methyl, trifluoromethyl, methoxy or hydroxyl and —C(═O)NH2;
- R5 is selected from the group consisting of hydrogen, C1-C6alkyl, phenyl, heteroaryl and C3-C10cycloalkyl, wherein said C1-C6alkyl, phenyl, heteroaryl and C3-C10cycloalkyl are optionally substituted with —C(═O)OH, —CH2OH, halogen, methyl, trifluoromethyl, methoxy or hydroxy;
- R6 is selected from the group consisting of hydrogen, C1-C6alkyl, tetrahydropyranyl and C3-C10cycloalkyl, wherein said C1-C6alkyl, tetrahydropyranyl, and C3-C10cycloalkyl are optionally substituted with one or two substituents independently selected from the group consisting of halogen and hydroxy;
- R7 is selected from the group consisting of hydrogen, C1-C6alkyl, tetrahydropyranyl and C3-C10cycloalkyl, wherein said C1-C6alkyl, tetrahydropyranyl, and C3-C10cycloalkyl are optionally substituted with one or two substituents independently selected from the group consisting of halogen and hydroxy;
- or R6 and R7 together with the nitrogen atom to which they are attached form a piperidine or a pyrrolidine ring, wherein said ring is optionally substituted with hydroxy or halogen;
- or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
A compound of the general formula (I):
- wherein R1 is selected from the group consisting of:
- wherein the symbol * denotes the point of attachment,
- R2 is selected from the group consisting of phenyl substituted with one or two independently selected R3 and pyridinyl substituted with one or two independently selected R3;
- R3 is selected from the group consisting of halogen, cyano, —C(═O)OH, —C(═O)R4, —CH(OH)R4, C(═O)—NR6R7, —OR4, —SR4, —S(═O)2R4, —S(═O)2—NR6R7, —C═CR4R5, —C≡C—R4R5, —C3-C10heterocyclyl optionally substituted with halogen or methyl, C3-C10cycloalkyl optionally substituted with halogen, methyl or hydroxy, phenyl optionally substituted with —C(═O)OH, halogen or methyl, C1-C6alkyl optionally substituted with R4 and heteroaryl optionally substituted with —C(═O)OH, halogen or methyl;
- R4 is selected from the group consisting of hydrogen, C1-C6alkyl, phenyl, heteroaryl and C3-C10cycloalkyl, wherein said C1-C6alkyl, phenyl, heteroaryl and C3-C10cycloalkyl are optionally substituted with —C(═O)OH, —CH2OH, halogen, methyl, trifluoromethyl, methoxy or hydroxyl and —C(═O)NH2;
- R5 is selected from the group consisting of hydrogen, C1-C6alkyl, phenyl, heteroaryl and C3-C10cycloalkyl, wherein said C1-C6alkyl, phenyl, heteroaryl and C3-C10cycloalkyl are optionally substituted with —C(═O)OH, —CH2OH, halogen, methyl, trifluoromethyl, methoxy or hydroxy;
- R6 is selected from the group consisting of hydrogen, C1-C6alkyl, tetrahydropyranyl and C3-C10cycloalkyl, wherein said C1-C6alkyl, tetrahydropyranyl, and C3-C10cycloalkyl are optionally substituted with one or two substituents independently selected from the group consisting of halogen and hydroxy;
- R2 is selected from the group consisting of hydrogen, C1-C6alkyl, tetrahydropyranyl and C3-C10cycloalkyl, wherein said C1-C6alkyl, tetrahydropyranyl, and C3-C10cycloalkyl are optionally substituted with one or two substituents independently selected from the group consisting of halogen and hydroxy;
- or R6 and R7 together with the nitrogen atom to which they are attached form a piperidine or a pyrrolidine ring, wherein said ring is optionally substituted with hydroxy or halogen;
- or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of 4-(2,4-Dichloro-phenoxy)-N-(5-hydroxy-adamantan-2-yl)-benzamide, 4-(5-Cyano-pyridin-2-yloxy)-N-(5-hydroxy-adamantan-2-yl)-benzamide, 4-(5-Chloro-pyridin-2-yloxy)-N-(5-hydroxy-adamantan-2-yl)-benzamide, 4-(5-Chloro-pyridin-2-yloxy)-N-(5-hydroxymethyl-adamantan-2-yl)-benzamide, and 4-(5-Chloro-pyridin-2-yloxy)-N-(4-hydroxymethyl-cyclohexyl)-N-methyl-benzamide.
11-15. (canceled)
Dependencies are inferred from the claim text.